Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEQTOR: Everolimus vs STZ-5FU Sequencing in pNETs
NCT02246127Phase 3Completed
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Oct 2014
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of everolimus in Pancreatic neuroendocrine tumor (PanNET), sponsored by Spanish Group of Neuroendocrine Tumors. Started Oct 2014; status: completed.
02
Drugs
everolimus
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02246127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02246127.